Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Stock Market Shifts into Small Caps

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 05, 2024 10:55am

75 Views

Post# 36164568

RE:RE:RE:RE:RE:RE:Stock Market Shifts into Small Caps

The healthcare sector has a history of stability and outperformance during periods of both recession and inflation, however with the issues of patent expiration facing Big Pharma, their focus is M&A smaller biotech companies for growth and to help outperform the general market which the oil and gas traders on this message board are lamenting over.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?